(Q84375400)

English

The chimerical multi-component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection

scientific article published on 08 August 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

The chimerical multi-component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Leishmania infantum

1 reference

based on heuristic

inferred from title

Juan Carlos Parejo

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Inés M. Corraliza

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

J Carcelén

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

V Iniesta

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

J Fernández-Cotrina

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

F Serrano

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

A Gallardo-Soler

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

F Marañón

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

M Soto

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

C Alonso

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

C Gómez-Nieto

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

8 August 2009

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

27

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

43

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

5964-5973

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

The relationship between leishmaniasis and AIDS: the second 10 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Leishmania-HIV interaction: immunopathogenic mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Leishmaniasis reservoirs and their significance in control

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Leishmania vaccines: old and new.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Recent advances in vaccines for leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S�o Gon�alo do Amarante, RN)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG + Q mix protects Balb/c mice from infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Analysis of the humoral immune response against total and recombinant antigens of Leishmania infantum: correlation with disease progression in canine experimental leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Clinical spectrum of Leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Canine leishmaniasis: identification of asymptomatic carriers by polymerase chain reaction and immunoblotting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Advantages of real-time PCR assay for diagnosis and monitoring of canine leishmaniosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: Double-blind randomised efficacy field trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Immunology of canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Cytokine expression during the outcome of canine experimental infection by Leishmania infantum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Humoral and cell-mediated immunity in natural and experimental canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Cell mediated immunity and specific IgG1 and IgG2 antibody response in natural and experimental canine leishmaniosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Leishmania major infection in susceptible and resistant mice elicit a differential humoral response against a total soluble fraction and defined recombinant antigens of the parasite

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Molecular determinants and regulation of Leishmania virulence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Antigen presentation by macrophages harboring intravesicular pathogens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.069

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.07.069

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19666153%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84375400&oldid=2135595512"